PRECISION BIOSCIENCES INC — Form 8-K
Filed November 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 99/100
What the filing says
Precision BioSciences priced an underwritten offering on November 5, 2026 of 10,235,077 shares at $7.75/share and 5,893,964 pre-funded warrants at $7.749995/warrant, generating ~$125M gross proceeds before fees. Underwriters: TD Securities USA LLC and Guggenheim Securities LLC. Net proceeds to fund PBGENE-HBV and PBGENE-DMD development and working capital. Closing expected November 6, 2026.
Why this rating
Raises $125M gross (likely ~$110–115M net after ~$5–10M fees) for a $47.1M market cap company—250%+ of current valuation. Dramatic capital infusion materially changes cash runway and development trajectory for gene-editing candidate pipeline.
Tradability signal
NO TRADE
No trade: positive news with only -3.2% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -2.70% over 4 hrs, n=20). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $9.85 ▲ 1.60% | at our read · unknown $9.70 | +10 min · unknown $9.13 ▼ 5.78% | +30 min · unknown $9.41 ▼ 2.91% | +1 hr · unknown $9.46 ▼ 2.42% | +4 hrs · unknown $10.16 ▲ 4.85% |
The stock had already moved -1.57% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.